

The logo for PHARMAC (Te Pātaka Whaioranga) is a white circle containing the text 'PHARMAC' in a large, bold, sans-serif font, with 'TE PĀTAKA WHAIORANGA' in a smaller, all-caps, sans-serif font below it. The background of the entire page is a complex, abstract pattern of white and grey lines that form a series of overlapping, concentric, and spiraling shapes, resembling a stylized 'P' or a series of interlocking loops.

PHARMAC
TE PĀTAKA WHAIORANGA

Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Update

August 2022

Contents

Summary of Pharmac decisions effective 1 August 2022	3
Tender News	5
Looking Forward	5
Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to August 2022.....	6
New Listings.....	18
Changes to Restrictions, Chemical Names and Presentations	21
Changes to Subsidy and Manufacturer’s Price.....	24
Delisted Items	27
Items to be Delisted	28
Index.....	30

Summary of Pharmac decisions

EFFECTIVE 1 AUGUST 2022

New listings (pages 18-20)

- Olsalazine (Atnahs Olsalazine) tab 500 mg – S29 and wastage claimable
- Sodium cromoglicate (Ralicrom) cap 100 mg
- Bisacodyl (Bisacodyl Viatris) tab 5 mg – only on a prescription
- Levocarnitine (Carnitor) oral liq 1 g per 10 ml, 118 ml – Special Authority – Retail pharmacy, s29 and wastage claimable
- Alfacalcidol (One-Alpha S29) cap 1 mcg – S29 and wastage claimable
- Zoledronic acid (Zoledronic acid Viatris) inj 4 mg per 5 ml, vial – Special Authority – Retail pharmacy
- Testosterone undecanoate (Steril-Gene) cap 40 mg – subsidy by endorsement, s29 and wastage claimable
- Cefalexin (Flynn) grans for oral liq 25 mg per ml and 50 mg per ml, 100 ml – wastage claimable
- Ethosuximide (Essential Ethosuximide) cap 250 mcg – S29 and wastage claimable
- Dexamfetamine sulfate (Aspen) tab 5 mg – Special Authority – Retail pharmacy, only on a controlled drug form, safety medicine; prescriber may determine dispensing frequency, s29 and wastage claimable
- Durvalumab inj 50 mg per ml, 2.4 ml and 10 ml vial (Imfinzi) and inj 1 mg for ECP (Baxter) – PCT only – Specialist – Special Authority
- Pharmacy services (BSF Aspen) brand switch fee – may only be claimed once per patient
- Desferrioxamine mesilate (Deferoxamine Pfizer S29) inj 500 mg vial – S29 and wastage claimable
- Extensively hydrolysed formula powder, 450 g OP (Pepti-Junior) and powder, 900 g OP (AllerPro Syneo 1 and AllerPro Syneo 2) – Special Authority – Hospital pharmacy [HP3]
- High fat low carbohydrate formula (KetoCal 4:1) powder (unflavoured and vanilla) 300 g OP – Special Authority – Retail pharmacy

Changes to restrictions (pages 21-22)

- Dexamfetamine sulfate (Aspen and PSM) tab 5 mg – addition of brand switch fee
- Olaparib (Lynparza) tab 100 mg and 150 mg – amended Special Authority criteria

Summary of Pharmac decisions – effective 1 August 2022 (continued)

Increased subsidy (pages 24-26)

- Loperamide hydrochloride (Diamide Relief) cap 2 mg
- Omeprazole (Dr Reddy's Omeprazole) inj 40 mg ampoule with diluent
- Ferrous sulfate (Ferodan) oral liq 30 mg (6 mg elemental) per 1 ml, 500 ml
- Sodium chloride (Fresenius Kabi) inj 0.9%, 5 ml ampoule
- Digoxin tab 62.5 mcg (Lanoxin PG) and tab 250 mcg (Lanoxin)
- Sotalol (Mylan) tab 80 mg and 160 mg
- Furosemide [frusemide] (Furosemide-Baxter) inj 10 mg per ml, 2 ml ampoule
- Clobetasol propionate (Dermol) crm 0.05% and oint 0.05%, 30 g OP and scalp app 0.05%, 30 ml OP
- Tamsulosin hydrochloride (Tamsulosin-Rex) cap 400 mcg
- Phenoxymethylpenicillin (penicillin v) (AFT) grans for oral liq 125 mg per 5 ml and 250 mg per 5 ml, 100 ml
- Tenoxicam (Tilcotil) tab 20 mg
- Ropinirole hydrochloride (Ropin) tab 0.25 mg, 1 mg, 2 mg and 5 mg
- Lidocaine [lignocaine] (Instillagel Lido) gel 2%, 11 ml urethral syringe
- Paracetamol with codeine (Paracetamol + Codeine (Relieve)) tab paracetamol 500 mg with codeine phosphate 8 mg
- Paroxetine (Loxamine) tab 20 mg
- Fludarabine phosphate inj 50 mg vial (Fludarabine Ebewe) and inj 50 mg for ECP (Baxter)
- Prednisolone acetate (Prednisolone-AFT) eye drops 1%, 10 ml OP

Decreased subsidy (pages 24-26)

- Ferrous sulfate (Ferrograd) tab long-acting 325 mg (105 mg elemental)
- Sodium chloride (Fresenius Kabi) inj 0.9%, 10 ml ampoule
- Losartan potassium with hydrochlorothiazide (Arrow-Losartan & Hydrochlorothiazide) tab 50 mg with hydrochlorothiazide 12.5 mg
- Gefitinib (Iressa) tab 250 mg
- Budesonide with eformoterol powder for inhalation 200 mcg with eformoterol fumarate 6 mcg (Symbicort Turbuhaler 200/6), 120 dose OP and powder for inhalation 400 mcg with eformoterol fumarate 12 mcg (Symbicort Turbuhaler 400/12), 60 dose OP

Increased price but not subsidy (page 25)

- Acetic acid with hydroxyquinoline and ricinoleic acid (Aci-Jel) Jelly with glacial acetic acid 0.94%, hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator, 100 g OP
-

Tender News

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) changes – effective 1 September 2022

Chemical Name	Presentation; Pack size	PSS/ SSS	PSS/SSS brand (and supplier)
Carbimazole	Tab 5 mg; 100 tab	PSS	Neo-Mercazole (AFT)
Colchicine	Tab 500 mcg; 100 tab	PSS	Colgout (Aspen)
Oil in water emulsion	Crm; 500 g	PSS	Fatty Cream AFT (AFT)
Promethazine hydrochloride	Tab 10 mg; 50 tab	PSS	Allersoothe (AFT)
Promethazine hydrochloride	Tab 25 mg; 50 tab	PSS	Allersoothe (AFT)
Spirolactone	Tab 25 mg; 100 tab	PSS	Spiractin (Viatrix)
Spirolactone	Tab 100 mg; 100 tab	PSS	Spiractin (Viatrix)

Looking Forward

This section is designed to alert both pharmacists and prescribers to possible future changes to the Pharmaceutical Schedule. It may also assist pharmacists, distributors and wholesalers to manage stock levels.

Decisions for implementation 1 September 2022

- Erlotinib (Alchemy) tab 100 mg and 150 mg – new listing
- Methadone hydrochloride (Methadone BNM) tab 5 mg – new listing
- Naloxone hydrochloride (Hameln) inj 400 mcg per ml, 1 ml ampoule – new listing

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to August 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Acarbose	Tab 50 mg & 100 mg	Accarb	2024
Aciclovir	Eye oint 3%, 4.5 g OP	VirusPOS	2024
Acitretin	Cap 10 mg & 25 mg	Novatretin	2023
Allopurinol	Tab 100 mg & 300 mg	DP-Allopurinol	2023
Ambrisentan	Tab 5 mg & 10 mg	Ambrisentan Mylan	2023
Amitriptyline	Tab 10 mg, 25 mg & 50 mg	Arrow-Amitriptyline	2023
Amlodipine	Tab 2.5 mg, 5 mg & 10 mg	Vasorex	2023
Amorolfine	Nail soln 5%, 5 ml OP	MycosNail	2023
Amoxicillin	Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml	Alphamox 125 Alphamox 250	2023
Amoxicillin with clavulanic acid	Tab 500 mg with clavulanic acid 125 mg	Curam Duo 500/125	2023
Anastrozole	Tab 1 mg	Anatrole	2023
Apomorphine hydrochloride	Inj 10 mg per ml, 5 ml ampoule Inj 10 mg per ml, 2 ml ampoule	Movapo	2023
Aprepitant	Cap 2 x 80 mg and 1 x 125 mg	Emend Tripack	2024
Aqueous cream	Crn, 500 g	GEM Aqueous Cream	2024
Atenolol	Tab 50 mg & 100 mg	Mylan Atenolol	2024
Atorvastatin	Tab 10 mg, 20 mg, 40 mg & 80 mg	Lorstat	2024
Atropine sulphate	Inj 600 mcg per ml, 1 ml ampoule Eye drops 1%, 15 ml OP	Martindale Atropt	2024 2023
Azithromycin	Tab 500 mg	Zithromax	2024
Bacillus calmette-guerin vaccine	Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin), Danish strain 1331, live attenuated, vial with diluent	BCG Vaccine	2024
Baclofen	Inj 2 mg per ml, 5 ml ampoule	Medsurge	2024
Bendroflumethiazide [Bendrofluazide]	Tab 2.5 mg & 5 mg	Arrow- Bendrofluazide	2023
Benzatropine mesylate	Inj 1 mg per ml, 2 ml	Phebra	2023
Benzylpenicillin sodium [Penicillin G]	Inj 600 mg (1 million units) vial	Sandoz	2023
Betahistine dihydrochloride	Tab 16 mg	Serc	2023
Betamethasone dipropionate	Crn & oint 0.05%, 50 g OP	Diprosone	2023
Betamethasone dipropionate with calcipotriol	Oint 500 mcg with calcipotriol 50 mcg per g, 30 g OP Gel 500 mcg with calcipotriol 50 mcg per g, 60 g OP	Daivobet	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to August 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Betamethasone valerate	Lotn 0.1%, 50 ml OP Oint 0.1%, 50 g OP Crn 0.1%, 50 g OP Scalp app 0.1%, 100 ml OP	Betnovate Beta Ointment Beta Cream Beta Scalp	2024
Bicalutamide	Tab 50 mg	Binarex	2023
Bimatoprost	Eye drops 0.03%, 3 ml OP	Bimatoprost Multichem	2024
Bisacodyl	Tab 5 mg Suppos 10 mg	Pharmacy Health Lax-suppositories	2024
Bisoprolol fumarate	Tab 2.5 mg, 5 mg & 10 mg	Bisoprolol Mylan	2023
Bosentan	Tab 62.5 mg & 125 mg	Bosentan Dr Reddy's	2024
Brimonidine tartrate	Eye drops 0.2%, 5 ml OP	Arrow-Brimonidine	2024
Brinzolamide	Eye drops 1%, 5 ml OP	Azopt	2024
Budesonide	Metered aqueous nasal spray, 50 mcg & 100 mcg per dose, 200 dose OP	SteroClear	2023
Bupropion hydrochloride	Tab modified-release 150 mg	Zyban	2023
Bezafibrate	Tab 200 mg Tab long-acting 400 mg	Bezalip Bezalip Retard	2024
Buspirone hydrochloride	Tab 5 mg & 10 mg	Buspirone Viatris	2024
Calamine	Crn, aqueous, BP, 100 g	Calamine-AFT	2024
Calcium carbonate	Tab 1.25 g (500 mg elemental)	Calci-Tab 500	2023
Candesartan cilexetil	Tab 4 mg, 8 mg, 16 mg & 32 mg	Candestar	2024
Capsaicin	Crn 0.025%, 45 g OP Crn 0.075%, 45 g OP	Zostrix Zostrix HP	2023
Cefazolin	Inj 500 mg & 1 g vial	AFT	2023
Cetirizine hydrochloride	Oral liq 1 mg per ml, 200 ml	Hisatclear	2024
Cetomacrogol	Crn BP, 500 g	Cetomacrogol-AFT	2024
Cinacalcet	Tab 30 mg & 60 mg	Cinacalcet Devatis	2024
Ciprofloxacin	Eye drops 0.3%, 5 ml OP Tab 250 mg, 500 mg & 750 mg	Ciprofloxacin Teva Cipflox	2024 2023
Citalopram hydrobromide	Tab 20 mg	PSM Citalopram	2024
Clarithromycin	Tab 250 mg & 500 mg	Klacid	2024
Clomipramine hydrochloride	Tab 10 mg & 25 mg	Clomipramine Teva	2024
Clonidine	Patch 2.5 mg, 100 mcg per day Patch 5 mg, 200 mcg per day Patch 7.5 mg, 300 mcg per day	Mylan	2023
Clonidine hydrochloride	Inj 150 mcg per ml, 1 ml ampoule Tab 150 mcg	Medsurge Catapres	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to August 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Codeine phosphate	Tab 15 mg, 30 mg & 60 mg	PSM	2023
Colecalciferol	Cap 1.25 mg (50,000 iu)	Vit.D3	2023
Condoms	60 mm	Shield XL	30/09/2022
	49 mm	Gold Knight	
	53 mm, 0.05 mm thickness	Moments	
	53 mm		
	53 mm, strawberry, red		
	53 mm, chocolate, brown		
	56 mm		
	56 mm, 0.08 mm thickness		
	56 mm, 0.08 mm thickness, red	Gold Knight	
	56 mm, 0.05 mm thickness		
56 mm, chocolate			
56 mm, strawberry			
Crotamiton	Crn 10%, 20 g OP	Itch-soothe	2024
Cyclizine hydrochloride	Tab 50 mg	Nausicalm	2024
Cyclophosphamide	Tab 50 mg	Cylconex	2024
Cyproterone acetate	Tab 50 mg & 100 mg	Siterone	2024
Cyproterone acetate with ethinyloestradiol	Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs	Ginet	2023
Darunavir	Tab 400 mg & 600 mg	Darunavir Mylan	2023
Desmopressin acetate	Nasal spray 10 mcg per dos, 6 ml OP	Desmopressin-PH&T	2023
Dexamethasone	Tab 0.5 mg & 4 mg	Dexmethsone	2024
Dexamfetamine sulfate	Tab 5 mg	PSM	2024
Diazepam	Tab 2 mg & 5 mg	Arrow-Diazepam	2023
Diclofenac	Eye drops 0.1%, 5 ml OP	Voltaren Ophtha	2024
Diclofenac sodium	Tab EC 25 mg & 50 mg	Diclofenac Sandoz	2024
Diltiazem hydrochloride	Cap long-acting 180 mg & 240 mg	Cardizem CD	2024
Diphtheria, tetanus and pertussis vaccine	Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml syringe	Boostrix	2024
Diphtheria, tetanus, pertussis and polio vaccine	Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin and 80 D-antigen units poliomyelitis virus in 0.5ml syringe	Infanrix IPV	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to August 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine	Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin, 80 D-AgU polio virus, 10 mcg hepatitis B surface antigen in 0.5ml syringe	Infanrix-hexa	2024
Disulfiram	Tab 200 mg	Antabuse	2024
Docusate sodium	Tab 50 mg & 120 mg	Coloxyl	2023
Domperidone	Tab 10 mg	Pharmacy Health	2024
Donepezil hydrochloride	Tab 5 mg & 10 mg	Donepezil-Rex	2023
Dorzolamide with timolol	Eye drops 2% with timolol 0.5%, 5 ml OP	Dortimopt	2024
Emulsifying ointment	Oint BP	Emulsifying Ointment ADE	2023
Entacapone	Tab 200 mg	Comtan	2024
Eplerenone	Tab 25 mg & 50 mg	Inspra	2024
Escitalopram	Tab 10 mg & 20 mg	Escitalopram (Ethics)	2024
Etanercept	Inj 25 mg Inj 50 mg autoinjector Inj 50 mg prefilled syringe	Enbrel	2024
Ezetimibe	Tab 10 mg	Ezetimibe Sandoz	2023
Febuxostat	Tab 80 mg & 120 mg	Febuxostat multicem	2023
Felodipine	Tab long-acting 5 mg Tab long-acting 10 mg	Felo 5 ER Felo 10 ER	2024
Fentanyl	Inj 50 mcg per ml, 2ml ampoule Inj 50 mcg per ml, 10 ml ampoule Patch 12.5 mcg per hour Patch 25 mcg per hour Patch 50 mcg per hour Patch 75 mcg per hour Patch 100 mcg per hour	Boucher and Muir Fentanyl Sandoz	2024
Ferrous fumarate	Tab 200 mg (65 mg elemental)	Ferro-tab	2024
Ferrous fumarate with folic acid	Tab 310 mg (100 mg elemental) with folic acid 350 mcg	Ferro-F-Tabs	2024
Filgrastim	Inj 300 mcg per 0.5 ml & 480 mcg per 0.5 ml	Nivestim	2024
Finasteride	Tab 5 mg	Ricit	2023
Flucloxacillin	Cap 250 mg & 500 mg Grans for oral liq 25 mg per ml Grans for oral liq 50 mg per ml Inj 1 g vial	Flucloxacillin-AFT AFT Flucil	2024 2023

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to August 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Fluconazole	Cap 50 mg, 150 mg & 200 mg	Mylan	2023
Fluorouracil sodium	Crn 5%, 20 g OP	Efudix	2024
Fluticasone	Aerosol inhaler 50 mcg, 125 mcg & 250 mcg per dose, 120 dose OP	Flixotide	2023
Fluticasone propionate	Metered aqueous nasal spray, 50 mcg per dose, 120 dose OP	Flixonase Hayfever & Allergy	2024
Fluticasone with salmeterol	Aerosol inhaler 50 mcg with salmeterol 25 mcg & 125 mcg with salmeterol 25 mcg, 120 dose OP	Seretide	2023
Folic acid	Tab 5 mg	Folic Acid Mylan	2024
Furosemide [frusemide]	Tab 40 mg	IPCA-Frusemide	2024
Gabapentin	Cap 100 mg, 300 mg & 400 mg	Nupentin	2024
Glibenclamide	Tab 5 mg	Daonil	2024
Glizclazide	Tab 80 mg	Glizide	2023
Glipizide	Tab 5 mg	Minidiab	2024
Glucagon hydrochloride	Inj 1 mg syringe kit	Glucagen Hypokit	2023
Glucose [Dextrose]	Inj 50%, 10 ml ampoule Inj 50%, 90 ml bottle	Biomed	2023
Glycerol	Liquid	healthE Glycerol BP	2023
Glyceryl trinitrate	Oint 0.2%, 30 g OP	Rectogesic	2024
Goserelin	Implant 3.6 mg & 10.8 mg, syringe	Teva	2023
Hepatitis A vaccine	Inj 1440 ELISA units in 1 ml syringe Inj 720 ELISA units in 0.5 ml syringe	Havrix Havrix Junior	2024
Hepatitis B recombinant vaccine	Inj 20 mcg per 1 ml prefilled syringe	Engerix-B	2024
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV]	Inj 270 mg in 0.5 ml syringe	Gardasil 9	2024
Hydrocortisone	Inj 100 mg vial	Solu-Cortef	2024
Hydrocortisone and paraffin liquid and lanolin	Lotn 1% with paraffin liquid 15.9% and lanolin 0.6%	DP Lotn HC	2023
Hydrocortisone butyrate	Oint 0.1%, 100 g OP Scalp lotn 0.1%, 100 ml OP Milky emuls 0.1%, 100 ml OP	Locoid Locoid Crelo	2024
Hydrocortisone with miconazole	Crn 1% with miconazole 2%, 15 g OP	Micreme H	2024
Hydroxyurea [hydroxycarbamide]	Cap 500 mg	Devatis	2023
Hyoscine butylbromide	Tab 10 mg Inj 20 mg, 1 ml	Buscopan	2023

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to August 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Ibuprofen	Oral liq 20 mg per ml, 200 ml Tab long-acting 800 mg Tab 200 mg	Ethics Brufen SR Relieve	2024
Imatinib mesylate	Cap 100 mg & 400 mg	Imatinib-Rex	2023
Indapamide	Tab 2.5 mg	Dapa-Tabs	2023
Ipratropium bromide	Aqueous nasal spray, 0.03%, 15 ml OP	Univent	2023
Isoniazid	Tab 100 mg	PSM	2024
Isoniazid with rifampicin	Tab 100 mg with rifampicin 150 mg Tab 150 mg with rifampicin 300 mg	Rifinah	2024
Isosorbide mononitrate	Tab 20 mg Tab long-acting 40 mg Tab long-acting 60 mg	ISMO 20 ISMO 40 Retard Duride	2023
Isotretinoin	Cap 5 mg, 10 mg & 20 mg	Oratane	2024
Ispaghula (psyllium) husk	Powder for oral soln, 500 g OP	Konsyl-D	2023
Ketoconazole	Shampoo 2%, 100 ml OP	Sebizole	2023
Labetalol	Tab 100 mg & 200 mg	Trandate	2024
Lamivudine	Tab 100 mg Tab 150 mg	Zetlam Lamivudine Alphapharm	2023
Lansoprazole	Cap 15 mg & 30 mg	Lanzol Relief	2024
Latanoprost	Eye drop 0.005%, 2.5 ml OP	Teva	2024
Latanoprost with timolol	Eye drops 0.005% with timolol 0.5%, 2.5 ml OP	Arrow - Lattim	2023
Leflunomide	Tab 10 mg & 20 mg	Arava	2023
Letrozole	Tab 2.5 mg	Letrole	2024
Levodopa with carbidopa	Tab long-acting 200 mg with carbidopa 50 mg Tab 100 mg with carbidopa 25 mg & 250 mg with carbidopa 25 mg	Sinemet CR Sinemet	2023
Levonorgestrel	Subdermal implant (2 x 75 mg rods) Intra-uterine device system 52 mg Intra-uterine device system 13.5 mg	Jadelle Mirena Jaydess	2023 31/10/2022
Lithium carbonate	Tab long-acting 400 mg	Priadel	2024
Lopinavir with ritonavir	Tab 100 mg with ritonavir 25 mg Tab 200 mg with ritonavir 50 mg	Lopinavir/Ritonavir Mylan	2024
Lorazepam	Tab 1 mg & 2.5 mg	Ativan	2024
Losartan potassium	Tab 12.5 mg, 25 mg, 50 mg & 100 mg	Losartan Actavis	2023

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to August 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride	Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg	Molaxole	2023
Magnesium sulphate	Inj 2 mmol per ml, 5 ml ampoule	Martindale	2023
Measles, mumps and rubella vaccine	Inj, measles virus 1,000 CCID50, mumps virus 5,012 CCID50, Rubella virus 1,000 CCID50; prefilled syringe/ampoule of diluent 0.5 ml	Priorix	2024
Mebendazole	Tab 100 mg	Vermox	2024
Mebeverine hydrochloride	Tab 135 mg	Colofac	2023
Melatonin	Tab modified-release 2 mg	Vigisom	2024
Meningococcal (groups A, C, Y and W-135) conjugate vaccine	Inj 4 mcg of each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial	Menactra	2024
Mesalazine	Tab long-acting 500 mg	Pentasa	2023
Methadone	Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml	Biodone Biodone Forte Biodone Extra Forte	2024
Methotrexate	Tab 2.5 mg & 10 mg Inj 100 mg per ml, 50 ml vial	Trexate Methotrexate Ebewe	2024 2023
Methylprednisolone aceponate	Crn & oint 0.1%, 15 g OP	Advantan	2023
Metoclopramide hydrochloride	Tab 10 mg	Metoclopramide Actavis 10	2023
Metoprolol tartrate	Tab 50 mg & 100 mg	IPCA-Metoprolol	2024
Metronidazole	Tab 200 mg & 400 mg	Metrogyl	2023
Metyrapone	Cap 250 mg	Metopirone	2023
Miconazole	Oral gel 20 mg per g, 40 g OP	Decozol	2024
Miconazole nitrate	Crn 2%, 15 g OP Vaginal crn 2% with applicator, 40 g OP	Multichem Micreme	2023
Mirtazapine	Tab 30 mg & 45 mg	Noumed	2024
Moclobemide	Tab 150 mg & 300 mg	Aurorix	2024
Modafinil	Tab 100 mg	Modavigil	2024
Mometasone furoate	Crn 0.1%, 15 g OP Crn 0.1%, 50 g OP Oint 0.1%, 15 g OP Oint 0.1%, 50 g OP Lotn 0.1%, 30 ml OP	Elocon Alcohol Free Elocon	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to August 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Morphine sulphate	Tab immediate-release 10 mg & 20 mg	Sevredol	2023
Moxifloxacin	Tab 400 mg	Avelox	2023
Nadolol	Tab 40 mg & 80 mg	Nadolol BNM	2024
Naltrexone hydrochloride	Tab 50 mg	Naltraccord	2023
Naproxen	Tab 250 mg Tab 500 mg Tab long-acting 750 mg Tab long-acting 1 g	Noflam 250 Noflam 500 Naprosyn SR 750 Naprosyn SR 1000	2024
Neostigmine metilsulfate	Inj 2.5 mg per ml, 1 ml ampoule	Max Health	2024
Nevirapine	Tab 200 mg	Nevirapine Alphapharm	2024
Nitrofurantoin	Cap modified-release 100 mg	Macrobid	2023
Norethisterone	Tab 350 mcg	Noriday 28	2024
Nystatin	Oral liq 100,000 u per ml, 24 ml OP Vaginal crm 100,000 u per 5 g with applicator(s), 75 g OP	Nilstat	2023
Octreotide	Inj 50 mcg per ml, 1 ml ampoule Inj 100 mcg per ml, 1 ml ampoule Inj 500 mcg per ml, 1 ml ampoule	Max Health	2024
Octreotide long-acting	Inj depot 10 mg, 20 mg & 30 mg prefilled syringe	Octreotide Depot Teva	2024
Oestriol	Crm 1 mg per g with applicator, 15 g OP Pessaries 500 mcg Tab 2 mg	Ovestin Ovestin	2023
Olanzapine	Orodispersible tab 5 mg & 10 mg Tab 2.5 mg, 5 mg and 10 mg	Zypine ODT Zypine	2023
Omeprazole	Cap 10 mg Cap 20 mg Cap 40 mg	Omeprazole actavis 10 Omeprazole actavis 20 Omeprazole actavis 40	2023
Ondansetron	Tab disp 4 mg & 8 mg	Ondansetron ODT-DRLA	2023
Ornidazole	Tab 500 mg	Arrow-Ornidazole	2024
Orphenadrine citrate	Tab 100 mg	Norflex	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to August 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Oxycodone hydrochloride	Inj 10 mg per ml, 1 ml and 2 ml ampoule	Hameln	2024
	Inj 50 mg per ml, 1 ml ampoule	Oxycodone Sandoz	
	Tab controlled-release 5 mg, 10 mg, 20 mg, 40 mg & 80 mg		
	Cap immediate-release 5 mg, 10 mg & 20 mg Oral liq 5 mg per 5 ml	OxyNorm	
Pancreatic enzyme	Cap prandreatin 150 mg (amylase 8,000 Ph Eur U lipase 10,000 Ph Eur U, total protease 600 Ph Eur U)	Creon 10000	2024
	Cap prandreatin 300 mg (amylase 18,000 Ph Eur U lipase 25,000 Ph Eur U, total protease 1,000 Ph Eur U)	Creon 25000	
Paracetamol	Tab 500 mg-bottle pack	Noumed Paracetamol	2024
	Tab 500 mg-blister pack	Pacimol	
	Oral liq 120 mg per 5 ml	Paracare	2023
	Oral liq 250 mg per 5 ml	Paracare Double Strength	
Perindopril	Tab 2 mg & 4 mg	Coversyl	2024
Permethrin	Crn 5%, 30 g OP	Lyderm	2023
	Lotn 5%, 30 ml OP	A-Scabies	
Pethidine hydrochloride	Tab 50 mg	PSM	2024
Phenoxymethylpenicillin (penicillin V)	Cap 250 mg	Cilicaine VK	2024
	Cap 500 mg		
Pimecrolimus	Crn 1%, 15 g OP	Eliidel	2023
Pine tar with trolamine laurilsulfate and fluorescein	Soln 2.3% with trolamine laurilsulfate and fluorescein sodium	Pinetarsol	2023
Pioglitazone	Tab 15 mg, 30 mg & 45 mg	Vexazone	2024
Pneumococcal (PCV10) conjugate vaccine	Inj 1 mcg of pneumococcal polysaccharide serotypes 1, 5, 6B, 7F, 9V, 14 and 23F; 3 mcg of pneumococcal polysaccharide serotypes 4, 18C and 19F in 0.5 ml prefilled syringe	Synflorix	2024
Pneumococcal (PPV23) polysaccharide vaccine	Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal serotype)	Pneumovax 23	2024
Poliomyelitis vaccine	Inj 80D antigen units in 0.5 ml syringe	IPOL	2024
Poloxamer	Oral drops 10%, 30 ml OP	Coloxyl	2023
Potassium iodate	Tab 253 mcg (150 mcg elemental iodine)	NeuroTabs	2023
Povidone iodine	Antiseptic solution 10%, 100 ml	Riodone	2024
	Oint 10%, 65 g OP	Betadine	2023
Pravastatin	Tab 20 mg & 40 mg	Pravastatin Mylan	2023

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to August 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Prednisolone	Oral liq 5 mg per ml, 30 ml OP	Redipred	2024
Prochlorperazine	Tab 5 mg	Nausafix	2023
Propranolol	Tab 10 mg Tab 40 mg	Drofate IPCA-Propranolol	2024
Pyridoxine hydrochloride	Tab 25 mg	Vitamin B6 25	2023
Quetiapine	Tab 25 mg, 100 mg, 200 mg & 300 mg	Quetapel	2023
Quinapril	Tab 5 mg Tab 10 mg Tab 20 mg	Arrow-Quinapril 5 Arrow Quinapril 10 Arrow-Quinapril 20	2024
Quinapril with hydrochlorothiazide	Tab 10 mg with hydrochlorothiazide 12.5 mg Tab 20 mg with hydrochlorothiazide 12.5 mg	Accuretic 10 Accuretic 20	2024
Rifampicin	Cap 150 mg & 300 mg Oral liq 100 mg per 5 ml	Rifadin	2023
Rifaximin	Tab 550 mg	Xifaxan	2023
Riluzole	Tab 50 mg	Rilutek	2024
Risperidone	Tab 0.5 mg, 1 mg, 2 mg, 3 mg & 4 mg Oral liq 1 mg per ml	Risperidone (Teva) Risperon	2023
Rituximab	Inj 100 mg per 10 ml vial & 500 mg per 50 ml vial	Riximyo	30/09/2023
Rivastigmine	Patch 4.6 mg per 24 hour Patch 9.5 mg per 24 hour	Rivastigmine Patch BNM 5 Rivastigmine Patch BNM 10	2024
Rizatriptan	Tab orodispersible 10 mg	Rizamelt	2023
Rosuvastatin	Tab 5 mg, 10 mg, 20 mg and 40 mg	Rosuvstatin Viatris	2023
Rotavirus oral vaccine	Oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose, prefilled oral applicator	Rotarix	2024
Salbutamol	Oral liq 400 mcg per ml, 150 ml Nebuliser soln 1 mg per ml, 2.5 ml ampoule Nebuliser soln 2 mg per ml, 2.5 ml ampoule	Ventolin Asthalin	2024
Salbutamol with ipratropium bromide	Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml ampoule	Duolin	2024
Sildenafil	Tab 25 mg, 50 mg & 100 mg	Vedafil	2024
Simvastatin	Tab 10 mg, 20 mg, 40 mg & 80 mg	Simvastatin Mylan	2023
Sodium citro-tartrate	Grans eff 4 g sachets	Ural	2023
Sodium fusidate [Fusidic acid]	Crn 2%, 5 g OP Oint 2%, 5 g OP	Foban	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to August 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Sodium hyaluronate [hyaluronic acid]	Eye drops 1 mg per ml, 10 ml OP	Hylo-Fresh	2024
Solifenacin succinate	Tab 5 mg & 10 mg	Solifenacin Mylan	2024
Somatropin (Omnitrope)	Inj 5 mg, 10 mg & 15 mg cartridge	Omnitrope	2024
Sumatriptan	Tab 50 mg & 100 mg	Sumagran	2024
Sunitinib	Cap 12.5 mg, 25 mg & 50 mg	Sunitinib Pfizer	2024
Tacrolimus	Oint 0.1%, 30 g OP	Zematop	2023
Taliglucerase alfa	Inj 200 unit vial	Elelyso	2023
Tamoxifen citrate	Tab 10 mg & 20 mg	Tamoxifen Sandoz	2023
Temazepam	Tab 10 mg	Normison	2023
Terbinafine	Tab 250 mg	Deolate	2023
Teriflunomide	Tab 14 mg	Aubagio	2023
Timolol	Eye drops 0.25% & 0.5%, 5 ml OP	Arrow-Timolol	2023
Tobramycin	Inj 40 mg per ml, 2 ml vial Solution for inhalation 60 mg per ml, 5 ml	Tobramycin Mylan Tobramycin BNM	2024 2023
Tramadol hydrochloride	Cap 50 mg Tab sustained-release 100 mg Tab sustained-release 150 mg Tab sustained-release 200 mg	Arrow-Tramadol Tramal SR 100 Tramal SR 150 Tramal SR 200	2023
Travoprost	Eye drops 0.004%, 2.5 ml OP	Travatan	2024
Tretinoin	Crn 0.5 mg per g, 50 g OP	ReTrieve	2024
Triamcinolone acetonide	Inj 10 mg per ml, 1 ml ampoule Inj 40 mg per ml, 1 ml ampoule Paste 0.1%, 5 g OP Crn & oint 0.02%, 100 g OP	Kenacort-A 10 Kenacort-A 40 Kenalog in Orabase Aristocort	2023
Trimethoprim	Tab 300 mg	TMP	2024
Trimethoprim with sulphamethoxazole [co-trimoxazole]	Tab trimethoprim 80 mg and sulphamethoxazole 400 mg	Trisul	2024
Tuberculin PPD [Mantoux] test	Inj 5 TU per 0.1 ml, 1 ml vial	Tubersol	2024
Ursodeoxycholic acid	Cap 250 mg	Ursosan	2023
Valaciclovir	Tab 500 mg & 1,000 mg	Valclovir	2024
Valganciclovir	Tab 450 mg	Valganciclovir Mylan	2024
Vancomycin	Inj 500 mg vial	Mylan	2023
Varenicline tartrate	Tab 0.5 mg x 11 and 1 mg x 42, 53 OP Tab 1 mg	Varenicline Pfizer	2024
Varicella vaccine [Chickenpox vaccine]	Inj 1350 PFU prefilled syringe	Varivax	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to August 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Zoledronic acid	Inj 4 mg per 5 ml, vial	Zoledronic Acid Mylan	2024
Zopiclone	Tab 7.5 mg	Zopiclone Actavis	2024

August 2022 changes are in bold type

**Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.*

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

New Listings

Effective 1 August 2022

7	OLSALAZINE Tab 500 mg.....	56.02	60	✓ Atnahs Olsalazine S29
	Wastage claimable			
8	SODIUM CROMOGLICATE Cap 100 mg	92.91	100	✓ Ralicrom
26	BISACODYL – Only on a prescription * Tab 5 mg.....	5.80	200	✓ Bisacodyl Viatris
29	LEVOCARNITINE – Special Authority see SA2040 – Retail pharmacy Oral liq 1 g per 10 ml	CBS	118 ml	✓ Carnitor S29
	Wastage claimable			
33	ALFACALCIDOL * Cap 1 mcg.....	87.98	100	✓ One-Alpha S29 S29
	Wastage claimable			
78	ZOLEDRONIC ACID Inj 4 mg per 5 ml, vial – Special Authority see SA2109 – Retail pharmacy	18.00	1	✓ Zoledronic acid Viatris
80	TESTOSTERONE UNDECANOATE Cap 40 mg – Subsidy by endorsement.....	35.00	100	✓ Steril-Gen S29
	a) Wastage claimable			
	b) Subsidy by endorsement – subsidised for patients who were taking testosterone undecanoate cap 40mg prior to 1 November 2021 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of testosterone undecanoate cap 40 mg in the preceding 12 months.			
89	CEFALEXIN Grans for oral liq 25 mg per ml – Wastage claimable.....	7.88	100 ml	✓ Flynn
	Grans for oral liq 50 mg per ml – Wastage claimable.....	10.38	100 ml	✓ Flynn
126	ETHOSUXIMIDE Cap 250 mg	78.89	56	✓ Essential Ethosuximide S29
	Wastage claimable			
137	DEXAMFETAMINE SULFATE – Special Authority see SA1149 – Retail pharmacy a) Only on a controlled drug form b) Safety medicine; prescriber may determine dispensing frequency Tab 5 mg.....	28.50	100	✓ Aspen S29
	Wastage claimable			

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

New Listings – effective 1 August 2022 (continued)

221	DURVALUMAB – PCT only – Specialist – Special Authority see SA2147			
	Inj 50 mg per ml, 2.4 ml vial	1,128.00	1	✓ Imfinzi
	Inj 50 mg per ml, 10 ml vial	4,700.00	1	✓ Imfinzi
	Inj 1 mg for ECP	9.59	1 mg	✓ Baxter
	▶ SA2147 Special Authority for Subsidy			
	Initial application – (Non-small cell lung cancer) only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:			
	Either:			
	1 Patient is currently on treatment with durvalumab and met all remaining criteria (criterion 2) below prior to commencing treatment; or			
	2 All of the following:			
	2.1 Patient has histologically or cytologically documented stage III, locally advanced, unresectable non-small cell lung cancer (NSCLC); and			
	2.2 Patient has received two or more cycles of platinum-based chemotherapy concurrently with definitive radiation therapy; and			
	2.3 Patient has no disease progression following the second or subsequent cycle of platinum-based chemotherapy with definitive radiation therapy treatment; and			
	2.4 Patient has a ECOG performance status of 0 or 1; and			
	2.5 Patient has completed last radiation dose within 8 weeks of starting treatment with durvalumab; and			
	2.6 Patient must not have received prior PD-1 or PD-L1 inhibitor therapy for this condition; and			
	2.7 Either:			
	2.7.1 Durvalumab is to be used at a maximum dose of no greater than 10 mg/kg every 2 weeks; or			
	2.7.2 Durvalumab is to be used at a flat dose of 1500 mg every 4 weeks; and			
	2.8 Treatment with durvalumab to cease upon signs of disease progression.			
	Renewal – (Non-small cell lung cancer) only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:			
	All of the following:			
	1 The treatment remains clinically appropriate and the patient is benefitting from treatment; and			
	2 Either:			
	2.1 Durvalumab is to be used at a maximum dose of no greater than 10 mg/kg every 2 weeks; or			
	2.2 Durvalumab is to be used at a flat dose of 1500 mg every 4 weeks; and			
	3 Treatment with durvalumab to cease upon signs of disease progression; and			
	4 Total continuous treatment duration must not exceed 12 months.			
241	PHARMACY SERVICES			
	May only be claimed once per patient.			
	* Brand switch fee	4.50	1 fee	✓ BSF Aspen
	a) The Pharmacode for BSF Aspen is 2641356.			
242	DEFERRIOXAMINE MESILATE			
	* Inj 500 mg vial	151.31	10	✓ Deroxamine Pfizer \$29 \$29
	Wastage claimable			
265	EXTENSIVELY HYDROLYSED FORMULA – Special Authority see SA1557 – Hospital pharmacy [HP3]			
	Powder	15.21	450 g OP	✓ Pepti-Junior
		30.42	900 g OP	✓ AllerPro Syneo 1 ✓ AllerPro Syneo 2

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

New Listings – effective 1 August 2022 (continued)

266	HIGH FAT LOW CARBOHYDRATE FORMULA – Special Authority see SA1197 – Retail pharmacy			
	Powder (unflavoured)	35.50	300 g OP	✓ KetoCal 4:1
	Powder (vanilla)	35.50	300 g OP	✓ KetoCal 4:1
	Note – these are new Pharmacode listings, 2639378 (unflavoured) and 2639386 (vanilla).			

Effective 1 July 2022

81	OESTRADIOL – See prescribing guideline			
	Patch 50 mcg per 24 hours	7.04	4	✓ Climara
	a) No more than 1 patch per week			
	b) Only on a prescription			
131	LEVOMEPRMAZINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency			
	Inj 25 mg per ml, 1 ml ampoule	16.75	5	✓ Neuraxpharm S29
	Wastage claimable			
215	TIXAGEVIMAB WITH CILGAVIMAB – [Xpharm] – Subsidy by endorsement			
	a) No patient co-payment payable			
	b) Treatment is funded only if patient meets access criteria for tixagevimab with cilgavimab (as on Pharmac's website) and has been endorsed accordingly by the prescriber. The supply of treatment is via Pharmac's approved distribution process. Refer to the Pharmac website for more information about this and stock availability.			
	Inj 150 mg per 1.5 ml with cilgavimab 150 mg per 1.5 ml	0.00	1	✓ Evusheld

Changes to Restrictions, Chemical Names and Presentations Effective 1 August 2022

137	DEXAMFETAMINE SULFATE – Special Authority see SA1149 – Retail pharmacy (addition of brand switch fee) a) Only on a controlled drug form b) Safety medicine; prescriber may determine dispensing frequency c) Brand Switch Fee payable (Pharmacode 2641356)				
	Tab 5 mg.....	28.50	100	✓ Aspen	\$29
		21.00		✓ PSM	
152	OLAPARIB – Retail pharmacy-Specialist – Special Authority see SA2148 1883 (amended Special Authority criteria) Tab 100 mg.....	3,701.00	56	✓ Lynparza	
	Tab 150 mg.....	3,701.00	56	✓ Lynparza	

➡ **SA2148 ~~1883~~** Special Authority for Subsidy

Initial application – (**Ovarian cancer**) only from a medical oncologist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

1 Patient is currently on treatment with olaparib and met all remaining criteria (criterion 2) below prior to commencing treatment; or

2 All of the following:

2.1 Patient has a high-grade serous* epithelial ovarian, fallopian tube, or primary peritoneal cancer; and

2.2 There is documentation confirming pathogenic germline BRCA1 or BRCA2 gene mutation; and

~~3 Patient has received at least two lines of previous treatment with platinum-based chemotherapy; and~~

~~4 Patient has platinum sensitive disease defined as disease progression occurring at least 6 months after the last dose of the penultimate line of platinum-based chemotherapy; and~~

~~5 Patient's disease must have achieved partial or complete response to treatment with the immediately preceding platinum-based regimen; and~~

~~6 Patient's disease has not progressed following prior treatment with olaparib; and~~

~~7 Treatment will be commenced within 8 weeks of the patient's last dose of the immediately preceding platinum-based regimen; and~~

2.3 Either:

2.3.1 All of the following:

2.3.1.1 Patient has newly diagnosed, advanced disease; and

2.3.1.2 Patient has received one line of previous treatment with platinum-based chemotherapy; and**

2.3.1.3 Patient's disease must have experienced a partial or complete response to the first-line platinum-based regimen; or

2.3.2 All of the following:

2.3.2.1 Patient has received at least two lines of previous treatment with platinum-based chemotherapy; and**

2.3.2.2 Patient has platinum sensitive disease defined as disease progression occurring at least 6 months after the last dose of the penultimate line of platinum-based chemotherapy; and**

2.3.2.3 Patient's disease must have experienced a partial or complete response to treatment with the immediately preceding platinum-based regimen; and

2.3.2.4 Patient has not previously received funded olaparib treatment; and

2.4 Treatment will be commenced within 12 weeks of the patient's last dose of the immediately preceding platinum-based regimen; and

2.5 Treatment to be administered as maintenance treatment; and

2.6 Treatment not to be administered in combination with other chemotherapy.

continued...

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Restrictions – effective 1 August 2022 (continued)

continued...

Renewal - (Ovarian cancer) only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from treatment; and
- ~~2 No evidence of progressive disease; and~~
- ~~3 Treatment to be administered as maintenance treatment; and~~
- ~~4 Treatment not to be administered in combination with other chemotherapy~~

2 Either:

- 2.1 No evidence of progressive disease; or**
- 2.2 Evidence of residual (not progressive) disease and the patient would continue to benefit from treatment in the clinician's opinion; and**

3 Treatment to be administered as maintenance treatment; and

4 Treatment not to be administered in combination with other chemotherapy; and

5 Either:

5.1 Both:

5.1.1 Patient has received one line of previous treatment with platinum-based chemotherapy; and**

5.1.2 Documentation confirming that the patient has been informed and acknowledges that the funded treatment period of olaparib will not be continued beyond 2 years if the patient experiences a complete response to treatment and there is no radiological evidence of disease at 2 years; or

5.2 Patient has received at least two lines of previous treatment with platinum-based chemotherapy.**

Note: *Note "high-grade serous" includes tumours with high-grade serous features or a high-grade serous component.

****A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.**

Effective 1 July 2022

270	INFLUENZA VACCINE (amended restriction criteria) Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine)	110.00	10	✓ Afluria Quad (2022 formulation)
	a) Only on a prescription			
	b) No patient co-payment payable			
	c)			
	A) INFLUENZA VACCINE – people 3 years and over is available each year for patients aged 3 years and over who meet the following criteria, as set by Pharmac:			
	a) all people 65 years of age and over; or			
	b) people 55 to 64 years of age (inclusive) who are Māori or any Pacific ethnicity; or			
	c) people under 65 years of age who:			
	i) have any of the following cardiovascular diseases:			
	a) ischaemic heart disease, or			
	b) congestive heart failure, or			
	c) rheumatic heart disease, or			
	d) congenital heart disease, or			
	e) cerebrovascular disease; or			
	ii) have either of the following chronic respiratory diseases:			
	a) asthma, if on a regular preventative therapy, or			
	b) other chronic respiratory disease with impaired lung function; or			
	iii) have diabetes; or			

continued...

Changes to Restrictions – effective 1 July 2022 (continued)

continued...

- iv) have chronic renal disease; or
- v) have any cancer, excluding basal and squamous skin cancers if not invasive; or
- vi) have any of the following other conditions:
 - a) autoimmune disease, or
 - b) immune suppression or immune deficiency, or
 - c) HIV, or
 - d) transplant recipients, or
 - e) neuromuscular and CNS diseases/disorders, or
 - f) haemoglobinopathies, or
 - g) are children on long term aspirin, or
 - h) have a cochlear implant, or
 - i) errors of metabolism at risk of major metabolic decompensation, or
 - j) pre and post splenectomy, or
 - k) down syndrome, or
- vii) are pregnant; or
- d) children 3 and 4 years of age (inclusive) who have been hospitalised for respiratory illness or have a history of significant respiratory illness; or
- e) people under 65 years of age who:**
 - i) have any of the following serious mental health conditions:**
 - a) schizophrenia; or**
 - b) major depressive disorder; or**
 - c) bipolar disorder; or**
 - d) schizoaffective disorder; or**
 - ii) are currently accessing secondary or tertiary mental health and addiction services; or**
- f) children 3 to 12 years of age (inclusive), from 1 July 2022 to 31 December 2022;**
Unless meeting the criteria set out above, the following conditions are excluded from funding:
 - a) asthma not requiring regular preventative therapy,
 - b) hypertension and/or dyslipidaemia without evidence of end-organ disease.
- B) Contractors will be entitled to claim payment for the supply of influenza vaccine to patients eligible under the above criteria pursuant to their contract with Health NZ for subsidised immunisation, and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.
- C) Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Subsidy and Manufacturer's Price

Effective 1 August 2022

6	LOPERAMIDE HYDROCHLORIDE – Up to 30 cap available on a PSO († subsidy) * Cap 2 mg 7.25	400	✓ Diamide Relief
9	OMEPRAZOLE († subsidy) * Inj 40 mg ampoule with diluent 37.38	5	✓ Dr Reddy's Omeprazole
35	FERROUS SULFATE (↓ subsidy) * Tab long-acting 325 mg (105 mg elemental) 2.55	30	✓ Ferrograd
35	FERROUS SULFATE († subsidy) * Oral liq 30 mg (6 mg elemental) per 1 ml 13.10	500 ml	✓ Ferodan
45	SODIUM CHLORIDE († subsidy) Not funded for use as a nasal drop. Not funded for nebuliser use except when used in conjunction with an antibiotic intended for nebuliser use. Inj 0.9%, 5 ml ampoule – Up to 5 inj available on a PSO 4.00	20	✓ Fresenius Kabi
45	SODIUM CHLORIDE (↓ subsidy) Not funded for use as a nasal drop. Not funded for nebuliser use except when used in conjunction with an antibiotic intended for nebuliser use. Inj 0.9%, 10 ml ampoule – Up to 5 inj available on a PSO 5.25	50	✓ Fresenius Kabi
48	LOSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE (↓ subsidy) Tab 50 mg with hydrochlorothiazide 12.5 mg 4.00	30	✓ Arrow-Losartan & Hydrochlorothiazide
49	DIGOXIN († subsidy) * Tab 62.5 mcg – Up to 30 tab available on a PSO 7.80 * Tab 250 mcg – Up to 30 tab available on a PSO 16.90	240	✓ Lanoxin PG ✓ Lanoxin
51	SOTALOL († subsidy) * Tab 80 mg 37.50 * Tab 160 mg 14.00	500 100	✓ Mylan ✓ Mylan
53	FUROSEMIDE [FRUSEMIDE] († subsidy) * Inj 10 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO 2.40	5	✓ Furosemide-Baxter
63	CLOBETASOL PROPIONATE († subsidy) * Crm 0.05% 2.40 * Oint 0.05% 2.33	30 g OP 30 g OP	✓ Dermol ✓ Dermol
69	CLOBETASOL PROPIONATE († subsidy) * Scalp app 0.05% 6.26	30 ml OP	✓ Dermol

Check your Schedule for full details Schedule page ref	Subsidy (Mnfr's price) \$	Per	Brand or Generic Mnfr ✓ fully subsidised
---	---------------------------------	-----	---

Changes to Subsidy and Manufacturer's Price – effective 1 August 2022 (continued)

75	ACETIC ACID WITH HYDROXYQUINOLINE AND RICINOLEIC ACID (↑ price but not subsidy) Jelly with glacial acetic acid 0.94%, hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator	8.43 (24.15)	100 g OP		Aci-Jel
76	TAMSULOSIN HYDROCHLORIDE – Special Authority see SA1032 – Retail pharmacy (↑ subsidy) * Cap 400 mcg.....	22.31	100	✓	Tamsulosin-Rex
93	PHENOXYMETHYLPENICILLIN (PENICILLIN V) (↑ subsidy) Grans for oral liq 125 mg per 5 ml	3.40	100 ml	✓	AFT
	a) Up to 200 ml available on a PSO b) Wastage claimable				
	Grans for oral liq 250 mg per 5 ml	4.24	100 ml	✓	AFT
	a) Up to 300 ml available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP c) Wastage claimable				
110	TENOXCAM (↑ subsidy) * Tab 20 mg.....	18.50	100	✓	Tilcotil
118	ROPINIROLE HYDROCHLORIDE (↑ subsidy) ▲ Tab 0.25 mg..... ▲ Tab 1 mg..... ▲ Tab 2 mg..... ▲ Tab 5 mg.....	4.05 4.95 6.48 14.50	84 84 84 84	✓ ✓ ✓ ✓	Ropin Ropin Ropin Ropin
119	LIDOCAINE [LIGNOCAINE] (↑ subsidy) Gel 2%, 11 ml urethral syringe – Subsidy by endorsement..... a) Up to 5 each available on a PSO b) Subsidised only if prescribed for urethral, cervical or rectal administration and the prescription is endorsed accordingly.	59.50	10	✓	Instillagel Lido
123	PARACETAMOL WITH CODEINE – Safety medicine; prescriber may determine dispensing frequency (↑ subsidy) * Tab paracetamol 500 mg with codeine phosphate 8 mg	27.50	1,000	✓	Paracetamol + Codeine (Relieve)
125	PAROXETINE (↑ subsidy) * Tab 20 mg.....	4.11	90	✓	Loxamine
147	FLUDARABINE PHOSPHATE (↑ subsidy) Inj 50 mg vial – PCT only – Specialist	634.00	5	✓	Fludarabine Ebewe
	Inj 50 mg for ECP – PCT only – Specialist.....	126.80	50 mg OP	✓	Baxter
158	GEFITINIB – Retail pharmacy-Specialist – Special Authority see SA2116 (↓ subsidy) Tab 250 mg.....	918.00	30	✓	Iressa

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Subsidy and Manufacturer's Price – effective 1 August 2022 (continued)

229	BUDESONIDE WITH EFORMOTEROL (↓ subsidy)				
	Powder for inhalation 200 mcg with eformoterol fumarate 6 mcg.....	33.74	120 dose OP	✓ Symbicort Turbuhaler 200/6	
	Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg – No more than 2 dose per day.....	33.74	60 dose OP	✓ Symbicort Turbuhaler 400/12	
238	PREDNISOLONE ACETATE (↑ subsidy)				
	Eye drops 1%	6.92	10 ml OP	✓ Prednisolone-AFT	

Delisted Items

Effective 1 August 2022

35	<p>FERROUS FUMARATE WITH FOLIC ACID * Tab 310 mg (100 mg elemental) with folic acid 350 mcg..... 4.68 60 ✓ Ferro-F-Tabs</p> <p>Note – this delist applies to Pharmacode 2219476.</p>
65	<p>AQUEOUS CREAM * Crm..... 1.73 500 g ✓ Boucher</p> <p>Note – delisting delayed until 1 October 2022.</p>
130	<p>AMISULPRIDE – Safety medicine; prescriber may determine dispensing frequency</p> <p>Tab 100 mg..... 5.15 30 ✓ Sulprix</p> <p style="text-align: right;">17.16 100 ✓ Amisulpride Mylan</p> <p style="text-align: right;">S29</p> <p>Note – the delist for Sulprix applies to Pharmacode 2500140.</p>
150	<p>BORTEZOMIB – PCT only – Specialist – Special Authority see SA1889 below</p> <p>Inj 2.5 mg vial..... 75.00 1 ✓ Bortezomib Juno</p> <p style="text-align: right;">S29 S29</p> <p>Inj 3.5 mg vial..... 105.00 1 ✓ Bortezomib Dr Reddy's</p> <p style="text-align: right;">S29 S29</p> <p style="text-align: right;">✓ Bortezomib Juno S29</p>

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Items to be Delisted

Effective 1 September 2022

91	ROXITHROMYGIN				
	Tab disp 50 mg	8.29	10		✓ Rulide-D
	Restricted to children under 12 years of age.				
	Note – delisting delayed until 1 March 2023.				

Effective 1 October 2022

65	AQUEOUS CREAM				
	* Crm	1.73	500 g		✓ Boucher

Effective 1 November 2022

241	PHARMACY SERVICES				
	May only be claimed once per patient.				
	* Brand switch fee	4.50	1 fee		✓ BSF Aspen
	a) The Pharmacode for BSF Aspen is 2641356.				
265	EXTENSIVELY HYDROLYSED FORMULA – Special Authority see SA1557 – Hospital pharmacy [HP3]				
	Powder	15.21	450 g OP		✓ Aptamil Gold+ Pepti Junior
		30.42	900 g OP		✓ Aptamil AllerPro SYNEO 1
					✓ Aptamil AllerPro SYNEO 2

Effective 1 January 2023

26	BISACODYL – Only on a prescription				
	* Tab 5 mg	5.80	200		✓ Pharmacy Health
45	WATER				
	1) On a prescription or Practitioner's Supply Order only when on the same form as an injection listed in the Pharmaceutical Schedule requiring a solvent or diluent; or				
	2) On a bulk supply order; or				
	3) When used in the extemporaneous compounding of eye drops; or				
	4) When used for the dilution of sodium chloride soln 7% for cystic fibrosis patients only.				
	Inj 20 ml ampoule – Up to 5 inj available on a PSO	5.00	20		✓ Multichem
89	CEFALEXIN				
	Grans for oral liq 25 mg per ml – Wastage claimable	8.75	100 ml		✓ Cefalexin Sandoz
	Grans for oral liq 50 mg per ml – Wastage claimable	11.75	100 ml		✓ Cefalexin Sandoz
118	ROPINIROLE HYDROCHLORIDE				
	▲ Tab 0.25 mg	3.39	100		✓ Mylan S29
125	PAROXETINE				
	* Tab 20 mg	3.61	90		✓ Loxamine
	Note – this delist applies to Pharmacode 2626799.				

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Items to be Delisted – effective 1 February 2023

93	PROCAINE PENICILLIN Inj 1.5 g in 3.4 ml syringe – Up to 5 inj available on a PSO	123.50	5	✓ Cilicaine
----	--	--------	---	-------------

Effective 1 March 2023

91	ROXITHROMYCIN Tab disp 50 mg	8.29	10	✓ Rulide D
	Restricted to children under 12 years of age.			

266	HIGH FAT LOW CARBOHYDRATE FORMULA – Special Authority see SA1197 – Retail pharmacy			
	Powder (unflavoured)	35.50	300 g OP	✓ KetoCal 4:1
	Powder (vanilla).....	35.50	300 g OP	✓ KetoCal 4:1
	Note – this delist applies to Pharmacodes, 2439778 (unflavoured) and 2400529 (vanilla).			

▲ Three months supply may be dispensed at one time if endorsed
“certified exemption” by the prescriber or pharmacist

* Three months or six months, as
applicable, dispensed all-at-once

Index

Pharmaceuticals and brands

A		
Acetic acid with hydroxyquinoline and ricinoleic acid	25	
Aci-Jel	25	
Afluria Quad (2022 formulation)	22	
Alfacalcidol	18	
AllerPro Syneo 1	19	
AllerPro Syneo 2	19	
Amisulpride.....	27	
Amisulpride Mylan	27	
Aptamil AllerPro SYNEO 1	28	
Aptamil AllerPro SYNEO 2	28	
Aptamil Gold+ Pepti Junior.....	28	
Aqueous cream.....	27, 28	
Arrow-Losartan & Hydrochlorothiazide	24	
Atrahs Olsalazine.....	18	
B		
Bisacodyl.....	18, 28	
Bisacodyl Viatris	18	
Bortezomib	27	
Bortezomib Dr Reddy's S29	27	
Bortezomib Juno	27	
Bortezomib Juno S29.....	27	
BSF Aspen	19, 28	
Budesonide with eformoterol	26	
C		
Carnitor.....	18	
Cefalexin	18, 28	
Cefalexin Sandoz.....	28	
Cilicaine	29	
Climara	20	
Clobetasol propionate.....	24	
D		
Deferoxamine Pfizer S29	19	
Dermol.....	24	
Desferrioxamine mesilate	19	
Dexamfetamine sulfate	18, 21	
Diamide Relief.....	24	
Digoxin	24	
Dr Reddy's Omeprazole.....	24	
Durvalumab	19	
E		
Essential Ethosuximide	18	
Ethosuximide	18	
Evusheld.....	20	
Extensively hydrolysed formula.....	19, 28	
F		
Ferodan	24	
Ferro-F-Tabs	27	
Ferrograd	24	
Ferrous fumarate with folic acid.....	27	
Ferrous sulfate	24	
Fludarabine Ebewe	25	
Fludarabine phosphate	25	
Frusemide.....	24	
Furosemide-Baxter	24	
Furosemide [Frusemide].....	24	
G		
Gefitinib	25	
H		
High fat low carbohydrate formula.....	20, 29	
I		
Imfinzi.....	19	
Influenza vaccine.....	22	
Instillagel Lido	25	
Iressa	25	
K		
KetoCal 4:1	20, 29	
L		
Lanoxin.....	24	
Lanoxin PG	24	
Levocarnitine	18	
Levomopromazine hydrochloride.....	20	
Lidocaine [Lignocaine].....	25	
Lignocaine	25	
Loperamide hydrochloride.....	24	
Losartan potassium with hydrochlorothiazide.....	24	
Loxamine	25, 28	
Lynparza.....	21	
O		
Oestradiol	20	
Olaparib	21	
Olsalazine	18	
Omeprazole.....	24	
One-Alpha S29.....	18	
P		
Paracetamol + Codeine (Relieve).....	25	
Paracetamol with codeine	25	
Paroxetine.....	25, 28	
Pepti-Junior	19	
Pharmacy services.....	19, 28	
Phenoxymethylpenicillin (Penicillin V)	25	
Prednisolone acetate	26	
Prednisolone-AFT.....	26	
Procaine penicillin	29	
R		
Ralicrom.....	18	
Ropin.....	25	
Ropinirole hydrochloride.....	25, 28	
Roxithromycin.....	28, 29	

Index

Pharmaceuticals and brands

Rulide D.....	28, 29	Tamsulosin-Rex	25
S		Tenoxicam	25
Sodium chloride.....	24	Testosterone undecanoate.....	18
Sodium cromoglicate	18	Tilcotil.....	25
Sotalol	24	Tixagevimab with cilgavimab	20
Steril-Genex.....	18	W	
Sulprix	27	Water.....	28
Symbicort Turbuhaler 200/6.....	26	Z	
Symbicort Turbuhaler 400/12.....	26	Zoledronic acid	18
T		Zoledronic acid Viatrix	18
Tamsulosin hydrochloride	25		

New Zealand
Permit No. 478



Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz

Email: enquiry@pharmac.govt.nz

ISSN 1172-9376 (Print)

ISSN 1179-3686 (Online)

Te Kāwanatanga o Aotearoa New Zealand Government

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand